What To Know
- , the leader in artificial intelligence-powered analysis of FCV, announced today it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.
- The primary objectives of the contract are to complete the execution of the clinical validation studies for COVID-19 and Influenza and to complete a de novo submission to the U.
Kitty Kolding, Co-Founder and CEO at RAIsonance
“We are elated to have BARDA’s support. Their strategic guidance and extensive expertise will speed our efforts to deliver the best possible diagnostic SaMD to market and help ensure that we fulfill our mission to meaningfully impact global health with such an innovative diagnostic solution.”